Plasma 8-hydroxy-2′-deoxyguanosine levels in Huntington disease and healthy controls treated with coenzyme Q10

Huntington Study Group Pre-2CARE Investigators

Research output: Contribution to journalArticle


We analyzed plasma 8OHdG concentrations in 20 individuals enrolled in the Pre-2CARE study before and after treatment with CoQ. Treatment resulted in a mean reduction in 8OHdG of 2.9 ± 2.9 pg/ml for the cohort (p = 0.0003) and 3.0 ± 2.6 pg/ml, for the HD group (p = 0.002). Baseline 8OHdG levels were not different between individuals with HD and controls (19.3 ± 3.2 pg/ml vs. 19.5 ± 4.7 pg/ml, p = 0.87) though baseline CoQ levels were elevated in HD compared with controls (p < 0.001). CoQ treatment reduces plasma 8OHdG and this reduction may serve as a marker of pharmacologic activity of CoQ in HD.

Original languageEnglish (US)
Pages (from-to)65-69
Number of pages5
JournalJournal of Huntington's Disease
Issue number1
StatePublished - 2012



  • 8OHdG
  • Huntington disease
  • coenzyme Q10
  • oxidative injury

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this